Caption Management’s Acceleron Pharma XLRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-1,700
Closed -$293K 2101
2021
Q3
$293K Sell
1,700
-68,300
-98% -$8.93M ﹤0.01% 1297
2021
Q2
$8.79M Buy
+70,000
New +$8.83M 0.11% 225
2020
Q3
Sell
-100,000
Closed -$9.53M 1366
2020
Q2
$9.53M Buy
100,000
+41,500
+71% +$4M 0.32% 61
2020
Q1
$5.26M Sell
58,500
-1,500
-3% -$117K 0.3% 89
2019
Q4
$3.18M Hold
60,000
0.11% 263
2019
Q3
$2.37M Buy
+60,000
New +$2.6M 0.12% 212
2018
Q3
Sell
-10,000
Closed -$485K 688
2018
Q2
$485K Buy
+10,000
New +$364K 0.04% 323

Caption Management's XLRN Position: Q4 2021 in Review

Caption Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 6,760 shares — an estimated $1.16M sold.

Caption Management first reported a position in XLRN in Q2 2018 and held it in 4 quarters. The position peaked at $2.94M in Q2 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Caption Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Caption Management sold 6,760 Acceleron Pharma shares in Q4 2021, an estimated $1.16M.
  • Caption Management first reported a position in Acceleron Pharma in Q2 2018 and held it in 4 quarters.
  • Caption Management's Acceleron Pharma position peaked at $2.94M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Caption Management's 13F filing for Q4 2021, filed 11 Feb 2022.